Long-term Efficacy of Baricitinib in Adults With Moderate to Severe Atopic Dermatitis Who Were Treatment Responders or Partial Responders: An Extension Study of 2 Randomized Clinical Trials

Follow up BREEZE-AD1/BREEZE-AD2 (n=2320) noted sustained efficacy, with proportions of responders/partial responders with validated Investigator Global Assessment for Atopic Dermatitis score of 0 or 1 achieved by 45.7% at wk 16 & 47.1% at wk 68 for 4mg (46.3% & 59.3% for 2mg).

JAMA Dermatology